Bergen Brunswig and Longs Drugs Expand Alliance

July 11, 2001
Orange, CA and Walnut Creek, CA - July 11, 2001 - Bergen Brunswig Drug Company (BBDC), a subsidiary of Bergen Brunswig Corporation (NYSE: BBC), and Longs Drug Stores (NYSE:LDG) have announced a new agreement naming Bergen as the exclusive fulfillment partner for Longs' on-line shopping. Bergen will supply over-the-counter products, health and beauty aids, and vitamins and dietary supplements for longs.com shoppers.

Longs recently added approximately 8,000 items to its online consumer services, which also offers prescription ordering and extensive health and wellness content. Patients ordering prescriptions on Longs' website can now select and purchase many of their favorite items online and have them delivered to their doorsteps by the next day, if desired. Non-prescription items are picked, packed and shipped by Bergen, whose direct-to-consumer dedicated facility, the Infinity Fulfillment Center, has established Bergen's leadership in the online fulfillment healthcare marketplace.

“This new agreement underscores the continuing and mutually beneficial relationship between Bergen and Longs,” said Chuck Prieve, Vice President, Strategic Client Development for Bergen. “We're excited to be part of the expansion of Longs' Internet offering and look forward to this new opportunity to provide quality products and services to Longs' loyal customers and enhance the growth and development of the longs.com name in the online health marketplace.”

T erry Burnside, Longs Senior Vice President and Chief Operating Officer, commented, “This agreement helps us significantly enhance our longs.com offering, providing our Internet customers with convenient, online access to many of their favorite items. Most importantly, our customers have a new channel to fulfill their needs - via the same drug store chain they know and trust.”

Longs Drug Stores Corporation is one of the leading drug store chains in North America. Founded in 1938 by brothers Joe and Tom Long as “Longs Self-Service Drugs,” the company currently operates 425 stores in California, Hawaii, Washington, Nevada, Colorado and Oregon. Annual sales average over $9.5 million per store. Longs’ unique strategy, focused on consumers’ health and well being, includes competencies in the key categories of pharmacy, over the counter medications, photo, and cosmetics, as well as other convenience offerings. Longs' website, located on the Internet at www.longs.com, blends consumer services and on-line shopping with extensive health and wellness information and also includes the latest company news and investor information.

Bergen Brunswig Corporation, headquartered in Orange County, California, is a leading supplier of pharmaceuticals and specialty healthcare products, as well as information management solutions and consulting services. Bergen's customers include the nation's healthcare providers (hospitals, nursing homes and physicians), drug stores, manufacturers and patients. Through its subsidiaries, Bergen provides product distribution, logistics, pharmacy management programs, and Internet fulfillment strategies designed to reduce costs and improve patient outcomes across the entire healthcare spectrum.

Except for historical information, all other information set forth in this press release, such as earnings forecasts and earnings rate projections, consists of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

These “forward-looking statements” are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those projected or implied. Such statements may be identified by the use of forward-looking language such as "may," "will," "should," "expect," "anticipate," "estimate," "believe," "think," "continue" or the negatives or other variations thereof or other similar terminology. Such risks and uncertainties include the risks described in exhibit 99(a) to the Company's Annual Report on Form 10-K for the year ended September 30, 2000 and in other reports and exhibits filed with the Securities and Exchange Commission. These risks and uncertainties include, but are not limited to, the costs and difficulties related to the integration of acquired businesses, the loss or disruption of one or more key customer or supplier relationships, changes in the distribution outsourcing pattern for pharmaceutical products and/or services, the ability to obtain general financing or financing rates that would be compatible with the Company's business operations, and the costs and other effects of governmental regulation and legal and administrative proceedings. The Company assumes no obligation to update the information in the release.